A new study published in the Journal of Drugs in Dermatology showed that while maintaining the integrity of the skin barrier, ...

A novel nutraceutical is an effective, well-tolerated therapy for the treatment of women with mild to moderate non-nodulocystic acne.

The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to potential rivals.

Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to ...

Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to ...

Black seed oil has been used as a natural remedy for centuries, even deriving inferences in several ancient Greek, Egyptian, Indian, and Arabian texts and healing traditions.It comes from Nigella ...

So, if you have acne-prone skin, check for the non-comedogenic value marker on every product on your shelf. 5. Hormonal imbalances: Hormonal disorders, especially around puberty, menstruation, and ...

Made with 99% natural ingredients and 1% salicylic acid derived from willow bark, a proven treatment for mild acne vulgaris, this is a gentle, plant-powered cleanser.

Bausch Health, Canada Inc, part of Bausch Health Companies Inc announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for Canadian public drug plan ...

The other approvals were for ARAZLO TM (tazarotene) lotion, 0.045% w/w, for the topical treatment of acne vulgaris in patients 10 years of age and older; BRYHALI (halobetasol propionate lotion 0. ...

CABTREO, a prescription product, is a topical gel that is administered once daily to affected areas of the skin. Its active ingredients are the antibiotic clindamycin phosphate, the topical retinoid ...

LAVAL, QC / ACCESS Newswire / April 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that it has signed a letter of intent with the ...